Form 4: Spyre Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Heidy King-Jones, See Remarks of Spyre Therapeutics, Inc., sold 28,399 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 27,999 Common Stock at $14.50 ($405,986) on September 1, 2026; holds 30,844 after (Direct).
- Open-market sale: disposed of 4,845 Common Stock at $86.40 ($418,608) on September 1, 2026; holds 25,999 after (Direct).
- Open-market sale: disposed of 16,548 Common Stock at $87.20 ($1,442,986) on September 1, 2026; holds 9,451 after (Direct).
- Open-market sale: disposed of 6,206 Common Stock at $88.17 ($547,183) on September 1, 2026; holds 3,245 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $89.38 ($35,752) on September 1, 2026; holds 2,845 after (Direct).
- Option exercise/conversion: acquired 400 Common Stock at $14.50 ($5,800) on September 2, 2026; holds 3,245 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $90.00 ($36,000) on September 2, 2026; holds 2,845 after (Direct).
- Option exercise/conversion: disposed of 27,999 Stock Option (Right to Buy) on September 1, 2026; holds 511,811 after (Direct).
- Option exercise/conversion: disposed of 400 Stock Option (Right to Buy) on September 2, 2026; holds 511,411 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,480,529 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Heidy King-Jones — Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 27,999 | $15 | $406.0K | 30,844 |
| 2026-09-01 | Open-market sale | Common Stock | 4,845 | $86 | $418.6K | 25,999 |
| 2026-09-01 | Open-market sale | Common Stock | 16,548 | $87 | $1.4M | 9,451 |
| 2026-09-01 | Open-market sale | Common Stock | 6,206 | $88 | $547.2K | 3,245 |
| 2026-09-01 | Open-market sale | Common Stock | 400 | $89 | $35.8K | 2,845 |
| 2026-09-02 | Option exercise/conversion | Common Stock | 400 | $15 | $5.8K | 3,245 |
| 2026-09-02 | Open-market sale | Common Stock | 400 | $90 | $36.0K | 2,845 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 27,999 | — | — | 511,811 |
| 2026-09-02 | Option exercise/conversion | Stock Option (Right to Buy) | 400 | — | — | 511,411 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (27,999 shares) |
| 2026-09-01 | Open-market sale (4,845 shares) |
| 2026-09-01 | Open-market sale (16,548 shares) |
| 2026-09-01 | Open-market sale (6,206 shares) |
| 2026-09-01 | Open-market sale (400 shares) |
| 2026-09-02 | Option exercise/conversion (400 shares) |
| 2026-09-02 | Open-market sale (400 shares) |
| 2026-09-01 | Option exercise/conversion (27,999 shares) |
| 2026-09-02 | Option exercise/conversion (400 shares) |
Keywords
insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Heidy King-Jones
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.